Mezzion

After independent review, study continues as planned with enrollment on track for completion in 2026 SEOUL, South Korea and FORT LEE, N.J., June 5, 2026 /PRNewswire/ -- Mezzion Pharma Co., Ltd. (KOSDAQ: 140410) today announced the results of a planned independent, blinded statistical review of its

SEOUL, South Korea, May 7, 2026 /PRNewswire/ -- Mezzion Pharma Co., Ltd. today announced written feedback from the U.S. Food and Drug Administration (FDA) following a pre-IND Type C Guidance meeting interaction for the development of udenafil in autosomal dominant polycystic kidney disease (ADPKD).

Institutional financing supports continued execution of late-stage program evaluating JURVIGO (udenafil) in patients living with Fontan circulation FORT LEE, N.J., May 14, 2026 /PRNewswire/ -- Mezzion Pharmaceuticals, Inc., a late-stage rare disease biopharmaceutical company focused on therapies

SEOUL, South Korea, April 16, 2025 /PRNewswire/ -- Mezzion Pharmaceuticals, a global leader in the development of therapies for patients with single ventricle heart disease, announces a transformative milestone for the Fontan community: the introduction of new, dedicated ICD-10 diagnosis codes for F

Dean Park is the founder, chairman, and chief executive officer of Mezzion Pharma Co., Ltd. and Mezzion Pharmaceuticals, Inc., where he leads long-term strategy and global growth.

Mezzion accepts inquiries about its udenafil clinical program.

Mezzion Pharmaceuticals, Inc. says its privacy policy explains the types of personal information it collects, how it uses and shares it, and privacy rights.